SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?
NCT04853615 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 800
Last updated 2021-04-26
Summary
We will look for the possible effect of SGLT2i as a single agent to prevent post-contrast Acute Kidney Injury in diabetic kidney disease.
Conditions
- SGLT2i Kideny Protection Against Contrast in Diabetic Kidney
Interventions
- DRUG
-
Empagliflozin 25 MG
PAtient will receive empagliflozin 25 mg daily
Sponsors & Collaborators
-
Cairo University
collaborator OTHER -
Fayoum University
lead OTHER
Eligibility
- Min Age
- 30 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-07-01
- Primary Completion
- 2024-07-01
- Completion
- 2024-08-01
- FDA Drug
- Yes
More Related Trials
-
PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria
NCT03168295 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
NCT05465317 ·Status: COMPLETED
-
meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis
NCT05715814 ·Status: RECRUITING ·Phase: PHASE3
-
SGLT2-inhibitors on PC-AKI
NCT06491953 ·Status: ACTIVE_NOT_RECRUITING
-
SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot
NCT06124924 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes
NCT04127084 ·Status: UNKNOWN ·Phase: PHASE4
-
Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life
NCT06759077 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).
NCT03713190 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease
NCT06982079 ·Status: RECRUITING ·Phase: PHASE3
-
SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome
NCT07214818 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes
NCT02796170 ·Status: COMPLETED ·Phase: PHASE4
-
Empagliflozin in ESKD - A Feasibility Study
NCT05687058 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients
NCT06421870 ·Status: RECRUITING ·Phase: PHASE3
-
Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients
NCT06897605 ·Status: RECRUITING ·Phase: PHASE2
-
The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors
NCT05360615 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Impact of Prior SGLT2 Inhibitors Use on the Development and Progression of Sepsis-Associated Acute Kidney Injury
NCT06902493 ·Status: COMPLETED
-
SGLT2i in Diabetic Patients with Renal Transplantation
NCT06731231 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
NCT05748925 ·Status: COMPLETED ·Phase: PHASE4
-
Prevent Diabetic Kidney Disease Among Egyptians
NCT06071208 ·Status: NOT_YET_RECRUITING
-
Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects
NCT02981966 ·Status: COMPLETED ·Phase: PHASE4
-
EFFECT SGLT2 INHIBITORS ON CONTRAST MEDIUM INDUCED ACUTE KIDNEY INJURY
NCT06288529 ·Status: COMPLETED
-
The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products
NCT02768220 ·Status: WITHDRAWN ·Phase: PHASE4
-
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy
NCT06668753 ·Status: NOT_YET_RECRUITING
-
Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors
NCT06825156 ·Status: COMPLETED ·Phase: PHASE4
-
SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia
NCT07344922 ·Status: COMPLETED ·Phase: PHASE3